Diltiazem
Cardizem, Cartia, Diltiazem, Teczem, Tiamate, Tiazac (diltiazem) is a small molecule pharmaceutical. Diltiazem was first approved as Cardizem on 1982-11-05. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1S. In addition, it is known to target potassium voltage-gated channel subfamily A member 1, cyclic nucleotide-gated channel alpha-3, voltage-dependent L-type calcium channel subunit alpha-1F, voltage-dependent L-type calcium channel subunit alpha-1D, potassium voltage-gated channel subfamily A member 5, cyclic nucleotide-gated channel alpha-1, cyclic nucleotide-gated channel beta-3, cyclic nucleotide-gated channel alpha-2, potassium voltage-gated channel subfamily A member 2, voltage-gated potassium channel KCNC1, voltage-dependent L-type calcium channel subunit alpha-1C, and potassium voltage-gated channel subfamily A member 7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Cardizem, Cartia, Diltiazem, Tiazac (discontinued: Cardizem, Dilacor, Dilt-cd, Diltiazem, Diltzac, Taztia, Tiamate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diltiazem hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARDIZEM | Bausch Health Companies | N-018602 RX | 1982-11-05 | 4 products, RLD |
| CARDIZEM CD | Bausch Health Companies | N-020062 RX | 1991-12-27 | 5 products, RLD |
| CARDIZEM LA | Bausch Health Companies | N-021392 RX | 2003-02-06 | 6 products, RLD, RS |
| TIAZAC | Bausch Health Companies | N-020401 RX | 1995-09-11 | 6 products, RLD |
Show 6 discontinued
Diltiazem malate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TIAMATE | Merck & Co | N-020506 DISCN | 1996-10-04 | 3 products |
Hide discontinued
Diltiazem malate
+
Enalapril maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TECZEM | Bausch Health Companies | N-020507 DISCN | 1996-10-04 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cardizem | ANDA | 2023-01-10 |
| cardizem cd | New Drug Application | 2020-04-30 |
| cardizem la | New Drug Application | 2019-09-23 |
| cartia | ANDA | 2022-02-05 |
| cartia xt | ANDA | 2022-04-19 |
| cartia xt | 2008-09-08 | |
| dilt-xr | 2007-03-31 | |
| diltiazem hci | ANDA | 2024-03-08 |
| diltiazem hcl | unapproved drug other | 2015-01-12 |
| diltiazem hcl cd | New Drug Application | 2023-06-08 |
Show 9 more
Indications
FDA
EMA
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AE: Muscle relaxants for treatment of hemorrhoids and anal fissures for topical use
— C05AE03: Diltiazem
— C08: Calcium channel blockers
— C08D: Selective calcium channel blockers with direct cardiac effects
— C08DB: Benzothiazepine derivative selective calcium channel blockers with direct cardiac effects
— C08DB01: Diltiazem
HCPCS
No data
Clinical
Clinical Trials
123 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 2 | 1 | 5 | 13 | 6 | 27 |
| Healthy volunteers/patients | — | — | — | 13 | — | — | 2 | — | 15 |
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 2 | 4 | 1 | 5 | 14 |
| Fissure in ano | D005401 | HP_0012390 | K60.2 | 2 | 3 | 3 | 1 | 3 | 10 |
| Atrial flutter | D001282 | EFO_0003911 | — | — | — | 1 | 5 | — | 6 |
| Coronary disease | D003327 | — | — | — | — | 2 | 3 | — | 5 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 3 | 1 | 4 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | 3 | — | 4 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | 1 | — | 2 | — | 4 |
| Covid-19 | D000086382 | — | — | — | 1 | — | 1 | 1 | 3 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 2 | — | 2 | 4 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | 3 | — | — | 4 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | 1 | 1 | — | 2 | 4 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | 3 | — | — | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 2 | — | — | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | 1 | — | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | 1 | — | — | 2 |
| Polycystic kidney diseases | D007690 | HP_0000113 | Q61.3 | — | — | 1 | — | — | 1 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | — | 1 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | — | 1 | — | — | 1 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial bridging | D054084 | — | — | — | 1 | — | — | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | 1 | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | 1 | — | — | — | 1 |
| Postoperative complications | D011183 | — | — | — | 1 | — | — | — | 1 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | 1 | — | — | — | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | — | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | 1 | — | — | — | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 1 | — | — | — | 1 |
| Skin ulcer | D012883 | HP_0200042 | L98.4 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | — | 3 |
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | 2 | — | — | — | — | 2 |
| Pharmacological phenomena | D000069437 | — | — | 2 | — | — | — | — | 2 |
| Surgical blood loss | D016063 | — | — | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adrenocortical adenoma | D018246 | — | — | — | — | — | — | 1 | 1 |
| Adrenal gland neoplasms | D000310 | EFO_0003850 | C74 | — | — | — | — | 1 | 1 |
| Fecal incontinence | D005242 | — | R15 | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
| Chest pain | D002637 | HP_0100749 | R07.9 | — | — | — | — | 1 | 1 |
| Hyperalgesia | D006930 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy-induced hypertension | D046110 | — | O13 | — | — | — | — | 1 | 1 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | — | — | 1 | 1 |
| Pathologic dilatation | D004108 | — | — | — | — | — | — | 1 | 1 |
| Coronary aneurysm | D003323 | EFO_1000881 | I25.41 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Diltiazem |
| INN | diltiazem |
| Description | Diltiazem is a 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension. It has a role as a calcium channel blocker, a vasodilator agent and an antihypertensive agent. It is a conjugate base of a diltiazem(1+). It is an enantiomer of an ent-diltiazem. |
| Classification | Small molecule |
| Drug class | calcium channel blockers (diltiazem type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 42399-41-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL23 |
| ChEBI ID | 101278 |
| PubChem CID | 39186 |
| DrugBank | DB00343 |
| UNII ID | EE92BBP03H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CNGA3
CNGA3
CNGA1
CNGA1
CNGB3
CNGB3
CNGA2
CNGA2
Organism
Homo sapiens
Gene name
CNGA3
Gene synonyms
CNCG3
NCBI Gene ID
Protein name
cyclic nucleotide-gated cation channel alpha-3
Protein synonyms
CNG channel alpha-3, CNG-3, CNG3, cone photoreceptor cGMP-gated channel alpha subunit, Cone photoreceptor cGMP-gated channel subunit alpha, cyclic nucleotide gated channel alpha 3, Cyclic nucleotide-gated channel alpha-3
Uniprot ID
Mouse ortholog
Cnga3 (12790)
cyclic nucleotide-gated cation channel alpha-3 (Q9WV01)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Diltiazem
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Diltiazem
+
Enalapril
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,220 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20,882 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use